ࡱ>  )` R]!bjbj2({{0\\\\\\\pxRxRxRxRdRLp2<4V4V4V4V4V4V4V4V$nh֙2E\y4V4Vyy\\4V4Vy\4V\4Vy\\4V(V `7gʚxR݋ 02:\ 4Vb bnkrW4V4V4V 4V4V4V2yyyyppp't+'pppt+ppp\\\\\\ & Scientific Program BIT s 8th Annual International Congress of Antibodies-2016 Theme: Accelerating the R&D of Next Generation Antibodies Time: April 25-28, 2016 Venue: Dalian International Conference Center (DICC), Dalian, China RegistrationTime: 08:30-18:00, April 24-25, 2016; Place: Dalian International Conference Center (DICC) Group PhotoTime: 08:20-08:30, April 25, 2016 (Monday); Place: South Outside of the Square, DICC Opening Ceremony and Plenary Forum Opening CeremonyTime: 09:00-10:00, April 25, 2016 (Monday); Place: Room 303, 3rd Floor, DICC Plenary ForumTime:10:00-12:10, April 25, 2016 (Monday); Place: Room 303, 3rd Floor, DICCModeratorDr. Mingde Xia,Senior Director, Johnson & Johnson Innovation, USA10:00-10:05Moderator's Introduction10:05-10:30Title:How to Model the Action of Complex Biological Systems on a Molecular Level Dr. Arieh Warshel,Distinguished Professor, University of Southern California, USA Nobel Prize Laureate in Chemistry, 201310:30-10:55Title:Understanding Human Health and Disease with LC/MS Based Metabolic Phenotyping Prof. Robert Plumb,Professor, Imperial College London, UK Fellow of the Royal Society of Chemistry10:55-11:20Title:A Novel Genetic System for Medical/Biotech Development of Longevity, Juvenescence, and Tumor Resistance Dr. Che-Kun James Shen,Distinguished Research Fellow, Institute of Molecular Biology, Academia Sinica, Taiwan Elected Fellow of the American Association for the Advancement of Science (AAAS) and the Third World Academy of Sciences, Academician of the Academia Sinica11:20-11:45Title:I Demonstrating Biosimilarity-A Foundation of the Biosimilar Development Dr. Patrick Liu,Vice President, Teva Pharmaceuticals Ltd., USA11:45-12:10Title:Bispecific Antibodies Finally Come of Age Dr. William Strohl,Vice President, Janssen Research & Development, LLC, USA Keynote Forum of ICA & WCV & PepConTime: 14:30-17:05, April 25, 2016 (Monday); Place: Room 307, 3rd Floor, DICCModeratorDr. Matthew He,Professor, Nova Southeastern University, USA14:30-14:35Moderator's Introduction14:35-15:05Title:Immunogenicity Assessment of Therapeutic Monoclonal Antibodies C Lab Testing and Clinical Impact Assessment Dr. Patrick Liu,Vice President, Teva Pharmaceuticals Ltd., USA15:05-15:35Title:The Promise of Peptide Drugs to Alleviate Medical Needs Dr. Jose de Chastonay,Chief Marketing Officer, Bachem Holding AG, Switzerland15:35-16:05Title:Present State and Challenges of Peptidomics Dr. Vadim T. Ivanov,Professor, Director, Russian Academy of Sciences, Russia16:05-16:35Title:Production and Purification of Virus like Particle (VLP) Based Vaccine Dr. Priyabrata Pattnaik,Director of Worldwide Vaccine Initiative, Merck , Singapore ICA 01: Patent Issues of Therapeutic Antibodies-A Comparative View Including China, India, Japan, USA and EuropeTime: 08:20-10:55, April26, 2016 (Tuesday) ; Place: Room 625, 6th Floor, DICCChairDr. Ulrich Storz,Senior Partner, MichalskiHuttermann & Partner, Germany08:20-08:25Chair's Introduction08:25-08:55Title:Patenting Antibody Inventions in China Mr. Lu Zuo,Patent Attorney, NTD Patent and Trademark Agency Limited, China08:55-09:25Title:Patent Protection of Antibody Drug in Japan Mr. Makoto Aihara,Managing Partner,SIKs & Co., Japan09:25-09:55Title:Antibody Patents in Europe: Possibilities and Limitations Dr. Ulrich Storz,Senior Partner, MichalskiHuttermann & Partner, Germany09:55-10:25Title:Antibody Patent Issues in the United States; Obtaining and Enforcing Antibody Patents and Challenging Them in the U.S. Patent Office under the New Patent Review Laws Mr. Colin Sandercock,Partner, Perkins Coie LLP, USA10:25-10:55Title:Trends and Challenges in Protecting and Enforcing Antibodies in India Mr. Tarun Gandhi ,Partner, Chadha & Chadha, IndiaCoffee Break ICA 02: New Technologies and Trends in Antibody ResearchTime: 08:20-11:25, April 26, 2016 (Tuesday) ; Place: Room 623, 6th Floor, DICCChairDr. Dan Zhang,Chairman and CEO, Fountain Medical Development Ltd., ChinaCo-ChairDr. Bodo Brocks,Director, Analytics & QC, Germany08:20-08:25Chair's Introduction08:25-08:45Title:Profiling ADME Properties of Biologics: Use of Radiolabels Ms. Denise OHara,Associate Research Fellow, Pfizer Inc., USA08:45-09:05Title:Biologic Immunomodulation by Human Intravenous Immunoglobulin Concentrate Dr. Paul August Imbach,Professor, University Children's Hospital Basel, Switzerland09:05-09:25Title:Conducting Biological Clinical Trial in New Regulatory Environment Dr. Dan Zhang,Chairman and CEO, Fountain Medical Development Ltd., China09:25-09:45Title:ClonePix2 High Throughput Technical Platform of Cell Line Development Mr. Guoqing Huang,Product Marketing Manager, Molecular Devices, China09:45-10:05Title:High Throughput Functional Assay Solutions for Therapeutic Antibody Screenings Dr. Xinpo Jiang,Director, GenScript, China10:05-10:25Title:A Platform for High-throughput Affinity Estimation of Antibodies Dr. Bodo Brocks,Director, Analytics & QC, Germany10:25-10:45Title:Antibody Discovery Using Yeast Display Ms. Lihui Xu,Associate Director, Merrimack Pharmaceuticals, Inc., USA10:45-11:05Title:The Predicted and Experimentally Confirmed Role of the Metabolic Minor Components in Intermolecular Interaction of the ABO System's Antigens Dr. Frida Gilmiyarova,Scientist, Samara State Medical University, Russia11:05-11:25Title:Antibody Libraries Based on an Autonomous Human Variable Domain Dr. Johan Nilvebrant,University of Toronto, Canada12:30-13:30Lunch ICA 03: Challenges and New Opportunities with Antibody and Protein DrugsTime: 13:30-17:10, April 26, 2016 (Tuesday) ; Place: Room 623, 6th Floor, DICCChairDr. William R Strohl,Vice President, Janssen Research & Development, LLC, USACo- ChairDr. Peter Pang,Director, JHL Biotech, USA13:30-13:35Chair's Introduction13:35-13:55Title:Online Measurements of Viable and Total Cell Densities Mr. Jochen Uhlenkuken,Manager, Hamilton Bonaduz AG, Switzerland13:55-14:15Title:Developing New Indication for Existing mAb Drug Dr. Feng Gao,CEO, BioKey, Inc, China14:15-14:35Title:From Basics to Application: Challenges and Solutions for Antibody Therapy Education for Future Pharmacists Dr. Yuan Zhao,Assistant Professor, Sullivan University College of Pharmacy, USA14:35-14:55Title:Protease-resistant Antibodies and Their Potential Use as Therapeutic Agents Dr. William R Strohl,Vice President, Janssen Research & Development, LLC, USA14:55-15:15Title:A Chemical Biology Approach for Mapping of Antibody Epitope Dr. Tony Velkov, Researcher, Monash University, Australia15:15-15:30Coffee Break15:30-15:50Title:Nonclinical Safety Testing of Biopharmaceuticals-currentChallenges and Opportunities Dr.Andreas Baumann, Director, Bayer Pharma AG, Germany15:50-16:10Title:High Quality and Affordable Biosimilars the Key for Success Dr. Rolf G. Werner,Professor, University Tuebingen, Germany16:10-16:30Title:Treatment of Autoimmune Diseases with Anti-IL-39 (p19/Ebi3) Antibody Dr. Renxi Wang,Associate Professor, Beijing Institute of Basic Medical Sciences, China16:30-16:50Title:Autoantibody Screening for Multiple Autoimmune Diseases Dr. Liping Yu,Director, University of Colorado School of Medicine, USA16:50-17:10Title:Challenges and Opportunities in Developing Novel Biologics toward IND Dr. Bin Chen,Director, Janssen R&D of Johnson & Johnson, USA17:10-18:00Panel Discussion ICA 04: Next Generation of Cancer Immune Therapy and Anti-cancer AntibodyTime: 08:30-11:50, April 27, 2016 (Wednesday) ; Place: Room 623, 6th Floor, DICCChairDr. Dimiter Dimitrov,Senior Investigator, National Cancer Institute, USACo-ChairDr. Ping Cao,Principal Scientist, Amgen Inc., USA08:30-08:35Chair's Introduction08:35-08:55Title:Biotherapeutics: Are They Designed by Evolution to Help? Dr. Gerd Birkenmeier,Professor, University of Leipzig, Germany08:55-09:15Title:Discovery and Translational Development of Novel Human Antibody for Treatment Resistant Cancer Dr. Bin Liu, Professor, University of California San Francisco, USA09:15-09:35Title:Human Monoclonal Antibodies as Candidate Therapeutics against Cancer and Viruses Dr. Dimiter Dimitrov,Senior Investigator, National Cancer Institute, USA09:35-09:55Title:Developing Human and Human-like Antibodies against Pathogens and Toxins for Diagnostics and Therapy Dr. Michael Hust,Professor, Technical University of Braunschweig, Germany10:15 -10:30Coffee Break10:30-10: 50Title:Strategies for Ranking and Selection of BiTE Molecule Candidates Dr. Ping Cao,Principal Scientist, Amgen Inc., USA10:50-11:10Title:An Enabling Technology for Nucleic Acid Antibody Discovery Dr. Xianbin Yang,Director, AM Biotechnologies LLC, USA11:10-11:30Title:NHP Modelsideal Efficacy Evaluation Systems for Antibody Therapeutics Dr. Jia Zeng,Director, Pharma Legacy Laboratories, China11:30-11:50Title:Rheumatoid Arthritis in Morocco Dr. Fzohra Zahra Alaoui,University Hospital Ibn Rochd, Morocco12:10-13:30Lunch ICA 05: Antibody Applications in Medical Diagnosis and Other Non-medical FieldTime: 15:40-17:25, April 27, 2016 (Wednesday) ; Place: Room 622, 6th Floor, DICCChairDr. Jian Zheng,President and CEO, Artron Bioresearch Inc.& Artron laboratory Inc., Canada15:40-15:45Chair's Introduction15:45-16:05Title:Analytical Evaluation of a BNP Assay on the New Point-of-care (POC) Platform Respons IQ Dr. Stephan Fellner,Project Manager, Pes Diagnosesysteme GmbH, Germany16:05-16:25Title:Direct Coupling of Immunoaffinity Chromatography and Capillary Isoelectric Focusing in a Unified Capillary Device Dr. Kiyohito Shimura,Professor, Fukushima Medical University, Japan16:25-16:45Title:The Research and Development Strategies of Monoclonal Antibodies against Phytase Dr. Jian Zheng,President and CEO, Artron Bioresearch Inc.& Artron laboratory Inc., Canada16:45-17:05Title:Evaluation of the Expression of Selected Acrosomal Sperm Proteins in Men with Normal and Pathological Spermiograms Using Monoclonal Antibodies Dr. Peknicova Jana,Director, Institute of Biotechnology AS CR, Czech Republic17:05-17:25Title:Low Levels of IgM Antibodies to Oxidized Cardiolipin Increase but High Levels Decrease Risk of Cardiovascular Disease in 60-year Olds from Stockholm County Dr. Hua Xiang,Karolinska University Hospital, Sweden17:25-18:00Panel Discussion ICA 06: Antibody Design, Engineering and ProductionTime: 08:30-11:50, April 28, 2016 (Thursday) ; Place: Room 622, 6th Floor, DICCChairDr. John Zhang,President, ABBIOSCI, Inc., USACo-ChairDr. David Han,Head of Biosimilar R & D, Merck Millipore Division, China08:30-08:35Chair's Introduction08:35-08:55Title:Understanding the Elimination Mechanisms of Antibody Therapeutics to Facilitate Antibody Engineering Dr. Mengmeng Wang,Principal Scientist, Pfizer, Inc., USA08:55-09:15Title:Optimization of Charge and Size Variants Separation of mAbs Using Dual pH/Salt Gradient Elution IEC Dr. Christian Frech,Professor, Mannheim University of Applied Sciences, Germany09:15-09:35Title:Lambody as Novel Specific Reagent for Discovery of Cancer Glycan Biomarkers Dr. John Zhang,President, ABBIOSCI, Inc., USA09:35-09:55Title:Challenges in Cell-line, Process and Analytical Development of a Single-chain Antibody and Solutions Dr. Hanuman Mallubhotla,Research Director, Syngene International Ltd, India09:55-10:15Title:Strategies for Clinical Trials to Support the Development of Antibody-based Therapeutics Mr. Yunsheng Hsieh,Senior Consultant, Protech Pharmaservices Corporation, Taiwan10:15-10:30Coffee Break10:30-10:50Title:Chemically Defined Cell Culture Media-boon and Bane of Trace Elements Dr. David Han,Head, Merck Millipore Division, China10:50-11:10Title:Development and Implementation of Tentacle Ion Exchangers: How Challenging Monoclonal Antibody Purification Tasks Can be Solved Dr. Lars Henrik Peeck,Senior Marketing Manager, Merck, Germany*8<> ʲiT R ?ukd$$If<   0634<abp yt l dF$1$Ifgd l$d9-D1$M a$gd ldF-D1$M gd l$d-D1$M a$gd l]! Q R S V a b c = > ? B O P Q V W     & p q κΣκΣκΣκۺttt,h lh l56CJKHOJQJ\]^J/h lh l5B*CJKHOJQJ\^Jph-h lh lB*CJKHOJQJ^JaJph&h lh l6CJKHOJQJ]^Jh lh lCJKHaJ h lh lCJKHOJQJ^J&h lh l5CJKHOJQJ\^J-R S V b y dF$1$Ifgd ldF-D1$M gd lfkd$$If< 0634<abyt lb c { dF$1$Ifgd lukd$$If<   0634<abp yt l y dF$1$Ifgd ldF-D1$M gd lfkdN$$If< 0634<abyt l > { dF$1$Ifgd lukd$$If<   0634<abp yt l> ? B P y dF$1$Ifgd ldF-D1$M gd lfkd$$If< 0634<abyt lP Q { dF$1$Ifgd lukd}$$If<   0634<abp yt l } dF$1$Ifgd l $$1$Ifa$gd lfkdL$$If< 0634<abyt l  vh dF$1$Ifgd l $$1$Ifa$gd l{kd$$If<0s 0634<abyt l   vh dF$1$Ifgd l $$1$Ifa$gd l{kd$$If<0s 0634<abyt l M N b -.F:;GN)bce ,DEFRY˷˷˷˷⠌˷˷&h lh l5CJKHOJQJ\^J-h lh lB*CJKHOJQJ^JaJph&h lh l6CJKHOJQJ]^J,h lh l56CJKHOJQJ\]^Jh lh lCJKHaJ h lh lCJKHOJQJ^J2 vh dF$1$Ifgd l $$1$Ifa$gd l{kd$$If<0s 0634<abyt l :vh dF$1$Ifgd l $$1$Ifa$gd l{kd>$$If<0s 0634<abyt l:;Gvh dF$1$Ifgd l $$1$Ifa$gd l{kd$$If<0s 0634<abyt lbvh dF$1$Ifgd l $$1$Ifa$gd l{kd $$If<0s 0634<abyt lbcerd dF$1$Ifgd ldF-D1$M gd l{kdx $$If<0s 0634<abyt l%fkd $$If< 0634<abyt l dF$1$Ifgd lfkd6 $$If< 0634<abyt l ,Eh{kd $$If<0s 0634<abyt l dF$1$Ifgd l $$1$Ifa$gd lEFRvh dF$1$Ifgd l $$1$Ifa$gd l{kdP $$If<0s 0634<abyt lZ\~rt  HI^ GHJ   #[\h|}~ǰǣǰǰǣǰǰǣǰǰǣxǣǣxǰǣxǣǰ&h lh l5CJKHOJQJ\^J-h lh lB*CJKHOJQJ^JaJphh lh lCJKHaJ,h lh l56CJKHOJQJ\]^J h lh lCJKHOJQJ^J&h lh l6CJKHOJQJ]^J&h lh l6CJKHOJQJ]^J/ vh dF$1$Ifgd l $$1$Ifa$gd l{kd$$If<0s 0634<abyt l  vh dF$1$Ifgd l $$1$Ifa$gd l{kd$$If<0s 0634<abyt lGvh dF$1$Ifgd l $$1$Ifa$gd l{kd$$If<0s 0634<abyt lGHJra$d9$1$Ifa$gd ldF-D1$M gd l{kdH$$If<0s 0634<abyt l x$d9$1$Ifa$gd lukd$$If<   0634<abp yt l  [w$d9$1$Ifa$gd l$d9$1$Ifa$gd lfkd$$If< 0634<abyt l[\h}sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdy$$If<0s 0634<abyt l}~sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd?$$If<0s 0634<abyt lDW{| '\o*+,12A|}ķķգķķķģķķķķķģķ-h lh lB*CJKHOJQJ^JaJph&h lh l5CJKHOJQJ\^Jh lh lCJKHaJ h lh lCJKHOJQJ^J,h lh l56CJKHOJQJ\]^J&h lh l6CJKHOJQJ]^J7{sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd$$If<0s 0634<abyt l{|sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd$$If<0s 0634<abyt l sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdy$$If<0s 0634<abyt lsb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd7$$If<0s 0634<abyt lss$d9$1$Ifa$gd l{kd$$If<0s 0634<abyt lra$d9$1$Ifa$gd ldF-D1$M gd l{kd$$If<0s 0634<abyt l+x$d9$1$Ifa$gd lukdq$$If<   0634<abp yt l+,2|w$d9$1$Ifa$gd l$d9$1$Ifa$gd lfkd:$$If< 0634<abyt l|}sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd$$If<0s 0634<abyt lsb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd$$If<0s 0634<abyt lisb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdh$$If<0s 0634<abyt l*=ijv})0s*^_krBSuv 6 L j k w | } ~ ķģķģķķģķķķķķģķ&h lh l5CJKHOJQJ\^Jh lh lCJKHaJ h lh lCJKHOJQJ^J&h lh l6CJKHOJQJ]^J,h lh l56CJKHOJQJ\]^J:ijvsb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd&$$If<0s 0634<abyt l)sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd$$If<0s 0634<abyt l^sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd$$If<0s 0634<abyt l^_ksb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd`$$If<0s 0634<abyt lusb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd$$If<0s 0634<abyt luvsb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd$$If<0s 0634<abyt lsb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd $$If<0s 0634<abyt lj se dF$1$Ifgd l$d9$1$Ifa$gd l{kdX!$$If<0s 0634<abyt lj k w } ss$d9$1$Ifa$gd l{kd"$$If<0s 0634<abyt l} ~ ra$d9$1$Ifa$gd ldF-D1$M gd l{kd"$$If<0s 0634<abyt l~ !!!! !4!6!o!p!y!z!!!!!!!!!!")"S"T"`"g"""""""<#K######$$<$=$I$P$$$$$$ööËöËööËöËöËöËöËö,h lh l56CJKHOJQJ\]^J&h lh l6CJKHOJQJ]^Jh lh lCJKHaJ h lh lCJKHOJQJ^J&h lh l5CJKHOJQJ\^J-h lh lB*CJKHOJQJ^JaJph6 !x$d9$1$Ifa$gd lukd#$$If<   0634<abp yt l!! !o!w$d9$1$Ifa$gd l$d9$1$Ifa$gd lfkda$$$If< 0634<abyt lo!p!z!!sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd%$$If<0s 0634<abyt l!!!!sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd%$$If<0s 0634<abyt l!!!S"sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd&$$If<0s 0634<abyt lS"T"`""sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdS'$$If<0s 0634<abyt l"""#sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd($$If<0s 0634<abyt l###<$sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd($$If<0s 0634<abyt l<$=$I$$sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd)$$If<0s 0634<abyt l$$$$ss$d9$1$Ifa$gd l{kdK*$$If<0s 0634<abyt l$$$$$$J%M%N%]%%%%%%%&&&#&h&w&x&&&&& ''S'T'U'a'h'''''' ( ( ( (V(W(X((((((((())۷۷۷۷۷۷ΌΣ۷-h lh lB*CJKHOJQJ^JaJph&h lh l6CJKHOJQJ]^J,h lh l56CJKHOJQJ\]^Jh lh lCJKHaJ h lh lCJKHOJQJ^J&h lh l5CJKHOJQJ\^J7$$$%sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd +$$If<0s 0634<abyt l%%%&sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd+$$If<0s 0634<abyt l&&&&sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd,$$If<0s 0634<abyt l&&&T'sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdC-$$If<0s 0634<abyt lT'U'a''se dF$1$Ifgd l$d9$1$Ifa$gd l{kd.$$If<0s 0634<abyt l''' (ss$d9$1$Ifa$gd l{kd.$$If<0s 0634<abyt l ( ( (W(ra$d9$1$Ifa$gd ldF-D1$M gd l{kd}/$$If<0s 0634<abyt lW(X((x$d9$1$Ifa$gd lukd;0$$If<   0634<abp yt l((((w$d9$1$Ifa$gd l$d9$1$Ifa$gd lfkd1$$If< 0634<abyt l(()7)sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd1$$If<0s 0634<abyt l))7)8)D)X)Y)Z)f)m)))))))Y*d*****+++L+M+Y+`+++,,,),*,+,8,?,,,,,,,--=->-J-Q-------..F.G.S.X.Y.Z.ططط&h lh l6CJKHOJQJ]^J&h lh l5CJKHOJQJ\^Jh lh lCJKHaJ h lh lCJKHOJQJ^J,h lh l56CJKHOJQJ\]^J@7)8)D)Y)sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdt2$$If<0s 0634<abyt lY)Z)f))sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd23$$If<0s 0634<abyt l)))*sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd3$$If<0s 0634<abyt l***L+sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd4$$If<0s 0634<abyt lL+M+Y+,sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdl5$$If<0s 0634<abyt l,,,*,ss$d9$1$Ifa$gd l{kd*6$$If<0s 0634<abyt l*,+,8,,sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd6$$If<0s 0634<abyt l,,,=-sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd7$$If<0s 0634<abyt l=->-J--sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdd8$$If<0s 0634<abyt l---F.sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd"9$$If<0s 0634<abyt lF.G.S.Y.ss$d9$1$Ifa$gd l{kd9$$If<0s 0634<abyt lY.Z.\..ra$d9$1$Ifa$gd ldF-D1$M gd l{kd:$$If<0s 0634<abyt lZ.[.\.......///_/`/l///////06070C0J0001111f1v11111c2d2x22222c3мssssssssss,h lh l56CJKHOJQJ\]^J&h lh l6CJKHOJQJ]^Jh lh lCJKHaJ h lh lCJKHOJQJ^J&h lh l5CJKHOJQJ\^J-h lh lB*CJKHOJQJ^JaJph/h lh l5B*CJKHOJQJ\^Jph-...x$d9$1$Ifa$gd lukd\;$$If<   0634<abp yt l../_/w$d9$1$Ifa$gd l$d9$1$Ifa$gd lfkd%<$$If< 0634<abyt l_/`/l//sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd<$$If<0s 0634<abyt l///60sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd=$$If<0s 0634<abyt l6070C01sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdS>$$If<0s 0634<abyt l1111sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd?$$If<0s 0634<abyt l1112sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd?$$If<0s 0634<abyt l2223sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd@$$If<0s 0634<abyt lc3r33333333333>4?4@4E4F4V4u4v4~44444444444c5v555556*6f6g6s6z6666667 7n777777طˠˌ˷˷ط&h lh l6CJKHOJQJ]^J-h lh lB*CJKHOJQJ^JaJph&h lh l5CJKHOJQJ\^Jh lh lCJKHaJ h lh lCJKHOJQJ^J,h lh l56CJKHOJQJ\]^J73333ss$d9$1$Ifa$gd l{kdKA$$If<0s 0634<abyt l3333ra$d9$1$Ifa$gd ldF-D1$M gd l{kd B$$If<0s 0634<abyt l33?4x$d9$1$Ifa$gd lukdB$$If<   0634<abp yt l?4@4F4u4w$d9$1$Ifa$gd l$d9$1$Ifa$gd lfkdC$$If< 0634<abyt lu4v444sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd:D$$If<0s 0634<abyt l4444sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdE$$If<0s 0634<abyt l4445sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdE$$If<0s 0634<abyt l555f6sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd|F$$If<0s 0634<abyt lf6g6s66sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd:G$$If<0s 0634<abyt l6677sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdG$$If<0s 0634<abyt l777z8sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdH$$If<0s 0634<abyt l7(8<8z8{888888888#9$909799999   f w       H!I!U!Z![!\!]!ķģķķķķķģķha>PU&h lh l5CJKHOJQJ\^Jh lh lCJKHaJ h lh lCJKHOJQJ^J,h lh l56CJKHOJQJ\]^J&h lh l6CJKHOJQJ]^J&z8{888ss$d9$1$Ifa$gd l{kdtI$$If<0s 0634<abyt l888#9sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kd2J$$If<0s 0634<abyt l#9$9099sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdJ$$If<0s 0634<abyt l99  sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdK$$If<0s 0634<abyt l11:10-11:30Title:In-depth Metabolomics for CHO: Compartment Specific Insights During mAB Production Dr. Ralf Takors,Director, University of Stuttgart, Germany11:30-11:50Title:Nanobody-based Cancer T-cell Immunotherapy Dr. Fusheng Li,President and Chief Scientist, Institute for Systems Vaccinology and Immunology, China12:30-13:30Lunch   H!sb$d9$1$Ifa$gd l$d9$1$Ifa$gd l{kdlL$$If<0s 0634<abyt lH!I!U![!ss$d9$1$Ifa$gd l{kd*M$$If<0s 0634<abyt l[!\!]!{kdM$$If<0s 0634<abyt l0182P. A!"#$%S $$If!vh5!#v!:V <  06,5/  / 34<p yt l$$If!vh5!#v!:V <06,5/  / 34<yt l$$If!vh5!#v!:V <  06,5/  / 34<p yt l$$If!vh5!#v!:V <06,5/  / 34<yt l$$If!vh5!#v!:V <  06,5/  / 34<p yt l$$If!vh5!#v!:V <06,5/  / 34<yt l$$If!vh5!#v!:V <  06,5/  / 34<p yt l$$If!vh5!#v!:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,55/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh5!#v!:V <065/  / 34<yt l$$If!vh5!#v!:V <065/  / 34<yt l$$If!vh55J#v#vJ:V <06,55/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh5!#v!:V <  065/  / 34<p yt l$$If!vh5!#v!:V <065/  / 34<yt l$$If!vh55J#v#vJ:V <06,55/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh5!#v!:V <  065/  / 34<p yt l$$If!vh5!#v!:V <065/  / 34<yt l$$If!vh55J#v#vJ:V <06,55/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh5!#v!:V <  06,5/  / 34<p yt l$$If!vh5!#v!:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,55/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh5!#v!:V <  065/  / 34<p yt l$$If!vh5!#v!:V <065/  / 34<yt l$$If!vh55J#v#vJ:V <06,55/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh5!#v!:V <  065/  / 34<p yt l$$If!vh5!#v!:V <065/  / 34<yt l$$If!vh55J#v#vJ:V <06,55/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh5!#v!:V <  065/  / 34<p yt l$$If!vh5!#v!:V <065/  / 34<yt l$$If!vh55J#v#vJ:V <06,55/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt l$$If!vh55J#v#vJ:V <06,5/  / 34<yt lN@N cke $1$a$$CJKHPJ_HaJmH nHsH tH$A@$ ؞k=W[SOBi@B nfh?BPQ:;Gbce ,EFR   / 0 < S T   "   '(*78:stQR^stUVb z{ab=>J_`lUVb%&2^_kxy'XYeABH~5 6 B !!!!!!L"M"Y""""j#k#w#######C$D$$$$$$%%%&%%%%&&&Y'Z'f'K(L(X(1)2)>)O)P)R)))))) ***`*a*m****5+6+B+++ ,,,,S-T-`-...,.-.9....///2030?0000000000000 @0 00 @0 0000 @0 00 @0 00000 @0 00 @0 0000 00 00 00 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 0000 00 00 00 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 0000 00 00 00 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 0000 00 00 00 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 0000 00 00 00 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 0000 00 00 00 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 0000 00 00 00 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 0000 00 00 00 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 00 00 @0 0RSVbc>?BPQ:;Gbce ,EFR   / 0 < S T   "   '(*78:stQR^stUVb z{ab=>J_`lUVb%&2^_kxy'XYeABH~5 6 B !!!!!!L"M"Y""""j#k#w#######C$D$$$$$$%%%&%%%%&&&Y'Z'f'K(L(X(1)2)>)O)P)R)))))) ***`*a*m****5+6+B+++ ,,,,S-T-`-...,.-.9....///2030?000000000000@ 0@ 00@ 0@ 000@ 0 @ 0 0 @ 0@ 00@ 000 0\0\@ 0\0\: 0\0\>@< 0\0\@ 0\0\A 0\0\@ 0 \@ 0"\0"\A 0$\0$\@ 0&\0&\@  0(\0(\@  0*\0*\@D 0,\0,\@ ȑ0 0.\0.\@ 00\@ 02\02\ 04\04\@$A` 06\06\@<<<< 08\08\d 0:0:A 0<0<@ 0>0>@ 0@0@ 0B0B@ 0DA 0F0F@ 0H0H@ 0J0J@ 0L0L@ 0N0N@ 0P0P@ 0R0R@ 0T0T@ 0V0V@ 0X0XA 0Z0Z@ 0\0\@ 0^0^ 0`0`@ 0bA 0d0d@i 0f0f@T 0h0h@XcV[ 0j0j@2[~? 0l0l@ 0n0n@ 0p0p@ 0r0r@ 0t0t@ 0v0v@ 0x0x@ 0z0z@ 0|0|@ 0~0~@ 00@ 00@ 0@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 0@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 0@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 00@ 0 0 @  00 ~ $)Z.c37]! *3<HS^ivR b > P  :bE G [}{+|i^uj } !o!!!S""#<$$$%&&T'' (W(((7)Y))*L+,*,,=--F.Y..._//60112333?4u4445f667z88#99 H![!]!!"#$%&'()+,-./012456789:;=>?@ABCDEFGIJKLMNOPQRTUVWXYZ[\]_`abcdefghjklmnopqrstuwxyz{|}~]!@[XvA[XdBwB[XBwC[XBwD[X$CwE[XdCwF[XCwG[XCwH[X$DwI[XdDwJ[XDwK[XDwL[X$EwM[XdEwN[XEwO[XEwP[X$FwQ[XdFwR[XFwS[XFwT[X$GwU[XdGwV[XGwW[XGwX[X$HwY[XdHwZ[XHw[[XHw\[X$Iw][XdIw^[XIw_[XIw`[X$Jwa[XdJwb[XJwc[XJwd[X$Kwe[XdKwf[XKwg[XKwh[X$Lwi[XdLwj[XLwk[XLwl[X$Mwm[XdMwn[XMwo[XMwp[X$Nwq[XdNwr[XNws[XNwt[X$Owu[XdOwv[XOww[XOwx[X$Pwy[XdPwz[XPw{[XPw|[X$Qw}[XdQw~[XQw[XQw[X$Rw[XdRw[XRw[XRw[X$Sw[XdSw[XSw[XSw[X$Tw[XdTw[XTw[XTw[X$Uw[XdUw[XUw[XUw[X$Vw[XdVw[XVw[XVw[X$Ww[XdWw[XWw[XWw[X$Xw[XdXw[XXw[XXw[X$Yw[XdYw[XYw[XYw[X$Zw[XdZw[XZw[XZw[X$[w[Xd[w[X[w[X[w[X$\w[Xd\w[X\w[X\w[X$]w[Xd]w[X]w[X]w[X$^w[Xd^w[X^w[X^w[X$_w[Xd_w[X_w[X_w[X$`w[Xd`w[X`w[X`w[X$aw[Xdaw[Xaw[Xaw[X$bw[Xdbw[Xbw[Xbw[X$cw[Xdcw[Xcw[Xcw[X$dw[Xddw[Xdw[Xdw[X$ew[Xdew[Xew[Xew[X$fw[Xdfw[Xfw[Xfw[X$gw[Xdgw[Xgw[Xgw[X$hw[Xdhw[Xhw[Xhw[X$iw[Xdiw[Xiw[Xiw[X$jw[Xdjw[Xjw[Xjw[X$kw[Xdkw[Xkw[Xkw[X$lw[Xdlw[Xlw[Xlw[X$mw[Xdmw[Xmw[Xmw[X$nw[Xdnw[Xnw[Xnw[X$ow[Xdow[Xow[Xow[X$pw[Xdpw[Xpw[Xpw[X$qw[Xdqw[Xqw[Xqw\X$rw\Xdrw\Xrw\Xrw\X$sw\Xdsw\Xsw\Xsw\X$tw \Xdtw \Xtw \Xtw \X$uw \Xduw\Xuw\Xuw\X$vw\Xdvw\Xvw\Xvw\X$ww\Xdww\Xww\Xww\X$xw\Xdxw\Xxw\Xxw\X$yw\Xdyw\Xyw\Xyw \X$zw!\Xdzw$$+9Dkkmv~~YY^   ( ( | | / 6 = D L J !::99CEIOOtt''RRs009OO~~AATRRmmuw__v  " " 1 H"H""""d#d#########$$%%u&u&&&&R'R'(( ) )*)R)R) * *Z*Z*1+1+,,M-M- . ...H/H////00*0U0U00000      !"#$%&'()+*,-./0126345789:;<=A>?@BCGDEFHIJKLPMNOQRSUTVWXYZ\[]a^_`bcdefhgikjlmnpoqsrtuvwxyz|{}~*8CJJttu}\aa    . . 4 ; B G R O   &&==BDGPPTT}  33qyy7<<TT''R]]WWtv~t}} ! / 4 4 K"K""""i#i#########$$%%&&&''X'X'((()0)0)U)U) * *_*_*4+4+,,R-R-....R/R////(01010t0t00000    !"#$%&'()+*,-./0124563789:;<=?@A>BCEFGDHIJKLNOPMQRSUTVWXYZ\[]_`a^bcdefhgikjlmnpoqsrtuvwxyz|{}~9*urn:schemas-microsoft-com:office:smarttagsState=*urn:schemas-microsoft-com:office:smarttags PlaceType=*urn:schemas-microsoft-com:office:smarttags PlaceNameB*urn:schemas-microsoft-com:office:smarttagscountry-region8*urn:schemas-microsoft-com:office:smarttagsCity9*urn:schemas-microsoft-com:office:smarttagsplace:*urn:schemas-microsoft-com:office:smarttagsStreet;*urn:schemas-microsoft-com:office:smarttagsaddress uz{BM25@D39^k!'^ g W Z   l q oy"&.ou]bt}LQRT49:E&)378;BH#-3AG JU LST\BFGR h!l!!!!"""4#7#8#<#H#N#########$$$$$$$$z%%%%%%%%%&!&,&X&`&&&''' '!''':'@'''''( (m(p(((() )).*8**+++++,,L,R,--2-9-------X/^/_/d//////0F0N0u0|000000M.\^ ][\^ ]III\^ ]{7"CvIIDG_um IYo")9u=mOT`7Yc[**hh0yi{O E h ! ` D}   ' h& '( % xK T - =L S[5lw1*<|CJ,.86RYboet  Tw"H%`hP^y Pp.()]b)MbR c i #!bz!g1"m"iX#$-$S$g$#%%pV%-&2&I&W&h&]*'1'8'P'^*(])H})*I*V*OZ,s_,-|X-2/2=2Gm2y2m+3=3N3D4j4X5w56G6 6;f675(7 :7u7|78:*8.H81%9`9:;-f;<<U<y< ==<$>v>z>5b?&2@dB@{@9AvfABBI0B7B;BSTBaC+C@CUgCDODEC8EPEcE>FLFWG[G#G-@GGGQGH'HT=H5iHW"IZJJ*UJpJwJwJ|K fKGLIL_LMekMuMezM@NSN OiOPa>PTUP)Q/Q'#RIREbRvSM T,-T^TUcUnUyU?VU\V{V!WgW~xW X4Y7Y mYe[E[Q[r[j\A\G\[L\P\Uf\{\ ]w]8^o^| _[;_`)`P`a5adaqaECbqc!cd d d'did*eR1eFeZe;|efVCfPfapf*)gigc#ha&h3,hW,h}.hehP$ikizinjADjgYjk()k l`lOmqn Bn[nhnTooQoIpp?qr)rQ0r4rYtrkwr`)sR3suJvPKvSvcvw)w=wRw>[wyiwwKx{)xDBx`UxcxyfyRz{${E{d{0y{||l.| @|\|q}RgeOj'z#  gj(IE4!*5).+"Av $)?D 06L(5a<FkrW!rD%0;:dC|Qh*p4>1Ct } _]fr>x7YpY(-=]'Ar3-{t:Dn*;cLwt 9\q7MAabhsG">:WIaU:(9OS!W,ZZ}-]|eS ^B;c%15?q8V! 0[ehuEI{>h8^Q=RV_a z(NMx %Kd;!J-G=Y/0"Wk4P+iFtKRZfR,L6Y|b=w"FPIi|Vn&7t:Q1px$x|}t||2"E;Q'1,;BHgQTQUl%_8G#S=BLWu$Y'aw  35z~J!O, 2OMTZ_n|/;BRqi"g/o^eEl_w"l'&CX(o8W] &$C)s_Q `e)8L m6*BP jogL]] _`R/%;?DJRyWyop~y%=d??_Ynzs#6Cr CR[Gu~@B[vn,7W^5;Z &9I*A\x!je #3$ @Aha1xEUwQ`W{v&C`T^q 5((5nD4FHw|#4zP <9.J?z?FS_=KRUfk3l:nRSVbc>?BPQ:;Gbce ,EFR   / 0 < S T   "   '(*78:stQR^stUVb z{ab=>J_`lUVb%&2^_kxy'XYeABH~5 6 B !!!!!!L"M"Y""""j#k#w#######C$D$$$$$$%%%&%%%%&&&Y'Z'f'K(L(X(1)2)>)O)P)R)))))) ***`*a*m****5+6+B+++ ,,,,S-T-`-...,.-.9....///2030?0000000@QQ] KQQ@ /0@@@@@(@@@@UnknownGz Times New Roman5Symbol3& z Arial;[SOSimSunI& ??Arial Unicode MS qhDgDgM)XM)X-!),.:;?]}    & 6"0000 0 0 00000 =@\]^([{  0 0 00000;[r002HX(? l2gr71Oh+'0h  $ 0 <HPX` Normal.dotgr712Microsoft Office Word@@[ʚ@ʚM)՜.+,D՜.+,|8   (0X0' ` ?GKSOProductBuildVer2052-9.1.0.3914  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~    Root Entry F0wʚ!Data N1TableWordDocument2(SummaryInformation( DocumentSummaryInformation8CompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q